BACKGROUND: @entity2239 -eluting bioresorbable vascular scaffolds have been developed to improve late outcomes after coronary interventions. However, recent registries raised concerns regarding an increased incidence of scaffold @entity715 (ScT). The mechanism of ScT remains unknown. METHODS AND RESULTS: The present study investigated angiographic and optical coherence tomography findings in @entity1 experiencing ScT. Fifteen ScT (14 @entity1 , 79% male, age 59  10 years) occurred at a median of 16 days (25%-75% interquartile range: 1-263 days) after implantation. Early ScT (<30 days) occurred in 8 cases (53%). Possible causal factors in these @entity1 included insufficient platelet inhibition in 2 cases and procedural factors (scaffold underexpansion, undersizing, or geographical miss) in 4 cases. No obvious cause could be found in 2 early ScT. In late (>1 month) and very late (>1 year) ScT (respectively, 5 and 2 cases), 5 scaffolds showed intimal neovessels or marked peristrut low-intensity areas. Scaffold @entity174 were additionally found in 2 @entity1 , and scaffold collapse was found in 1 @entity1 with very late ScT. Extensive strut malapposition was the presumed cause for ScT in 1 case. One scaffold did not show any @entity154 . Thrombectomy specimens were analyzed in 3 @entity1 and did not demonstrate increased numbers of inflammatory cells. CONCLUSIONS: The mechanisms of early ScT seem to be similar to metallic stents (mechanical and inadequate antiplatelet therapy). The predominant finding in late and very late ScT is peristrut low-intensity area.

Optical Coherence Tomography Findings in Bioresorbable Vascular Scaffolds XXXX .

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity154 :: ('MESH:D000013', 'Disease') :: ['morphological abnormality'] @entity174 :: ('MESH:D050723', 'Disease') :: ['fractures'] @entity2239 :: ('MESH:C107135', 'Chemical') :: ['Everolimus'] @entity715 :: ('MESH:D013927', 'Disease') :: ['thrombosis']
@entity715 :: (MESH:D013927,Disease) :: ['Thrombosis']
